Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol

Bone

Volumn 45, Issue 5, 2009, Pages 870-875

  Glendenning, Paul ^a,b   Chew, Gerard T ^a,b   Seymour, Hannah M ^a   Gillett, Melissa J ^a   Goldswain, Peter R ^a   Inderjeeth, Charles A ^b,c   Vasikaran, Samuel D ^a   Taranto, Mario ^a   Musk, Alexander A ^a   Fraser, William D ^d  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cholecalciferol; Equipotency; Ergocalciferol; Hip fractures; Vitamin D insufficiency

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM CARBONATE; COLECALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; PLACEBO; UNCLASSIFIED DRUG; VIGANTOLETTEN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIP FRACTURE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; ERGOCALCIFEROLS; HIP FRACTURES; HUMANS; PARATHYROID HORMONE; PATIENT COMPLIANCE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 70349298330     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.07.015     Document Type: Article

References (29)

1. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 22 (2001) 477-501
2. Baker M.R., McDonnell H., Peacock M., and Nordin B.E. Plasma 25-hydroxy vitamin D concentrations in patients with fractures of the femoral neck. Br. Med. J. 1 (1979) 589
3. Bruce D.G., St John A., Nicklason F., and Goldswain P.R. Secondary hyperparathyroidism in patients from Western Australia with hip fracture: relationship to type of hip fracture, renal function, and vitamin D deficiency. J. Am. Geriatr. Soc. 47 (1999) 354-359
4. Dawson-Hughes B., Harris S.S., Krall E.A., and Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337 (1997) 670-676
5. Chapuy M.C., Arlot M.E., Duboeuf F., Brun J., Crouzet B., Arnaud S., Delmas P.D., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327 (1992) 1637-1642
6. Working Group of the Australian and New Zealand Bone and Mineral Society; Endocrine Society of Australia; Osteoporosis Australia. Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med. J. Aust. 182 (2005) 281-285
7. Glendenning P. Issues of standardization and assay-specific clinical decision limits for the measurement of 25-hydroxyvitamin D. Am. J. Clin. Nutr. 77 (2003) 522-523
8. Glendenning P. Standardised, metabolite-specific assays with validated decision limits: utopian ideal or achievable goal?. Clin. Biochem. Rev. 26 (2005) 3-4
9. Glendenning P., Taranto M., Noble J.M., Musk A.A., Hammond C., Goldswain P.R., et al. Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann. Clin. Biochem. 43 (2006) 23-30
10. Armas L.A., Hollis B.W., and Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J. Clin. Endocrinol. Metab. 89 (2004) 5387-5391
11. Tjellesen L., Hummer L., Christiansen C., and Rodbro P. Serum concentration of vitamin D metabolites during treatment with vitamin D2 and D3 in normal premenopausal women. Bone Miner 1 (1986) 407-413
12. Trang H.M., Cole D.E., Rubin L.A., Pierratos A., Siu S., and Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am. J. Clin. Nutr. 68 (1998) 854-858
13. Holick M.F., Biancuzzo R.M., Chen T.C., Klein E.K., Young A., Bibuld D., et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J. Clin. Endocrinol. Metab. 93 (2008) 677-681
14. Romagnoli E., Mascia M.L., Cipriani C., Fassino V., Mazzei F., D'Erasmo E., et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J. Clin. Endocrinol. Metab. 93 (2008) 3015-3020
15. Lips P., Duong T., Oleksik A., Black D., Cummings S., Cox D., et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J. Clin. Endocrinol. Metab. 86 (2001) 1212-1221
16. Lips P., Wiersinga A., van Ginkel F.C., Jongen M.J., Netelenbos J.C., Hackeng W.H., et al. The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J. Clin. Endocrinol. Metab. 67 (1988) 644-650
17. Fleisch H. Can bisphosphonates be given to patients with fractures?. J. Bone Miner Res. 16 (2001) 437-440
18. Glendenning P., Musk A.A., Taranto M., and Vasikaran S.D. Preanalytical factors in the measurement of intact parathyroid hormone with the DPC IMMULITE assay. Clin. Chem. 48 (2002) 566-567
19. Whyte M.P., Haddad Jr. J.G., Walters D.D., and Stamp T.C. Vitamin D bioavailability: serum 25-hydroxyvitamin D levels in man after oral, subcutaneous, intramuscular, and intravenous vitamin D administration. J. Clin. Endocrinol. Metab. 48 (1979) 906-911
20. Holmberg I., Berlin T., Ewerth S., and Bjorkhem I. 25-Hydroxylase activity in subcellular fractions from human liver. Evidence for different rates of mitochondrial hydroxylation of vitamin D2 and D3. Scand. J. Clin. Lab. Invest. 46 (1986) 785-790
21. Guo Y.D., Strugnell S., Back D.W., and Jones G. Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8668-8672
22. Cheng J.B., Motola D.L., Mangelsdorf D.J., and Russell D.W. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J. Biol. Chem. 278 (2003) 38084-38093
23. Harwood R.H., Sahota O., Gaynor K., Masud T., and Hosking D.J. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham Neck of Femur (NONOF) Study. Age Ageing 33 (2004) 45-51
24. Noble J.M., McGuiness M., and Glendenning P. Low rate of compliance with ergocalciferol therapy in vitamin-D-deficient patients with hip fracture. Med. J. Aust. 177 (2002) 280
25. Frolich A., Storm T., and Thode J. Does the plasma concentration of 25-hydroxyvitamin D determine the level of 1,25-dihydroxyvitamin D in primary hyperparathyroidism?. Miner. Electrolyte Metab. 22 (1996) 203-206
26. Dent C.E., Jones P.E., and Mullan D.P. Masked primary (or tertiary) hyperparathyroidism. Lancet 1 (1975) 1161-1164
27. Glendenning P., Gutteridge D.H., Retallack R.W., Stuckey B.G., Kermode D.G., and Kent G.N. High prevalence of normal total calcium and intact PTH in 60 patients with proven primary hyperparathyroidism: a challenge to current diagnostic criteria. Aust. N. Z. J. Med. 28 (1998) 173-178
28. Tjellesen L., Gotfredsen A., and Christiansen C. Different actions of vitamin D2 and D3 on bone metabolism in patients treated with phenobarbitone/phenytoin. Calcif. Tissue Int. 37 (1985) 218-222
29. Tjellesen L., Christiansen C., Rodbro P., and Hummer L. Different metabolism of vitamin D2 and vitamin D3 in epileptic patients on carbamazepine. Acta Neurol. Scand. 71 (1985) 385-389